Tingting Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tingting Chen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Jian Zou
Department of Gynecology and Oncology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
1 shared publicationShizhou Yang
Department of Gynecology and Oncology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
1 shared publicationYanan Zhang
Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, People’s Republic of China
1 shared publicationYe Jin
Department of Gynecology and Oncology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
1 shared publication- Yuanming Shen
Department of Gynecologic Oncology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China
1 shared publication Zhu Cao
Department of Gynecology and Oncology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (1) , 41
CSN5 overexpression promotes the integral progression of cervical cancer by enhancing ENO3-mediated glycolysis
Cervical cancer (CC) remains a significant global health challenge. A deeper understanding of the molecular mechanisms driving CC progression is crucial for developing improved therapeutic strategies. CSN5 is vital in cell functions and cancer, but its role in CC is unclear. This study aims to explore CSN5’s role and its target gene in CC progression, assessing their potential as therapeutic targets. We employed an integrated approach combining bioinformatics analysis, proteomic profiling, and in vitro and in vivo functional assays. Immunohistochemistry was used to analyze CSN5 and ENO3 expression in CC and normal tissues. CSN5 upregulation was associated with advanced clinical stage and poor differentiation. Furthermore, CSN5 overexpression enhanced cellular proliferation and glycolytic metabolism but, paradoxically, suppressed migration, invasion, and the epithelial-mesenchymal transition (EMT). These pro-tumorigenic effects were confirmed in vivo, and the glycolytic inhibitor 2-DG was found to reverse the phenotypes induced by CSN5. Protein sequencing highlighted ENO3’s role in CSN5-mediated tumorigenesis, regulating EMT and glycolysis by stabilizing its ubiquitination degradation through CSN5. Crucially, silencing ENO3 attenuated the oncogenic effects of CSN5 both in vitro and in vivo. Our findings unveil a novel mechanistic paradigm in which CSN5 promotes CC progression by co-opting ENO3 to enhance glycolytic flux while concurrently suppressing cell motility. This study not only deepens the understanding of CC pathogenesis but also identifies the CSN5-ENO3 axis as a promising target for novel therapeutic interventions. Graphical abstract
- 12 January 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (1) , 41
Open AccessCSN5 overexpression promotes the integral progression of cervical cancer by enhancing ENO3-mediated glycolysis
Cervical cancer (CC) remains a significant global health challenge. A deeper understanding of the molecular mechanisms driving CC progression is crucial for developing improved therapeutic strategies. CSN5 is vital in cell functions and cancer, but its role in CC is unclear. This study aims to explore CSN5’s role and its target gene in CC progression, assessing their potential as therapeutic targets. We employed an integrated approach combining bioinformatics analysis, proteomic profiling, and in vitro and in vivo functional assays. Immunohistochemistry was used to analyze CSN5 and ENO3 expression in CC and normal tissues. CSN5 upregulation was associated with advanced clinical stage and poor differentiation. Furthermore, CSN5 overexpression enhanced cellular proliferation and glycolytic metabolism but, paradoxically, suppressed migration, invasion, and the epithelial-mesenchymal transition (EMT). These pro-tumorigenic effects were confirmed in vivo, and the glycolytic inhibitor 2-DG was found to reverse the phenotypes induced by CSN5. Protein sequencing highlighted ENO3’s role in CSN5-mediated tumorigenesis, regulating EMT and glycolysis by stabilizing its ubiquitination degradation through CSN5. Crucially, silencing ENO3 attenuated the oncogenic effects of CSN5 both in vitro and in vivo. Our findings unveil a novel mechanistic paradigm in which CSN5 promotes CC progression by co-opting ENO3 to enhance glycolytic flux while concurrently suppressing cell motility. This study not only deepens the understanding of CC pathogenesis but also identifies the CSN5-ENO3 axis as a promising target for novel therapeutic interventions. Graphical abstract